Takeda Pharmaceutical (TAK) news
Recent news
Sun Pharma: litigation relating to a settlement with Pfizer
Pfizer Inc. has reached a $2.15 billion settlement with Teva Pharmaceuticals and Sun Pharmaceutical Industries, resolving a decade-long patent-infringement dispute over the acid reflux drug Protonix. The settlement, announced on June 12, 2023, follows a jury ruling in New Jersey federal court that…
AInvest Wire · Aug 17, 2026Keros Therapeutics - received $200 mln upfront from Takeda, eligible for over $1.10 bln in milestones
AInvest Wire · Jul 30, 2026Keros Therapeutics - to receive $20 mln development milestone payment from Takeda
AInvest Wire · Jul 30, 2026Alembic Pharma: Nod for generic of Takeda's MoteGritty tablets
Alembic Pharma has received regulatory approval for the generic version of Takeda's Motegrity tablets, marking a significant development in the U.S. generics market. The drug, prucalopride, is indicated for the treatment of chronic idiopathic constipation in adults and functions as a serotonin-4…
AInvest Wire · Jul 28, 2026Moody's Ratings announces completion of a periodic review of ratings of Takeda Pharmaceutical Company Limited
AInvest Wire · Jul 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.